
Join to View Full Profile
1000 Pines Lake Dr WWayne, NJ 07470
Phone+1 516-817-1690
Dr. Paley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Carole Paley is a pediatric hematologist and oncologist based in Wayne, NJ, with extensive training and education, including a fellowship at Memorial Sloan Kettering Cancer Center, NYC Hospital and a pediatrics residency at the Icahn School of Medicine at Mount Sinai. She holds leadership and academic roles as the Executive Medical Director at Novartis Oncology and Associate Professor of Clinical Pediatrics at Albert Einstein College of Medicine. Her clinical experience includes specialized knowledge in myelofibrosis, hematopoietic cell transplantation, and myelodysplastic syndrome. Dr. Paley has authored several noteworthy publications on the safety and efficacy of ruxolitinib, highlighting her research's impact within the field. Additionally, she has received numerous awards, including the President's Award and Business Excellence Award from Novartis Oncology, and was recognized as one of the Top Doctors in the New York Area from 1999 to 2004.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
Icahn School of Medicine at Mount SinaiResidency, Pediatrics, 1984 - 1987
Ross University School of MedicineClass of 1984
Yale UniversityB.A., Philosophy/Psychology
New School for Social ResearchM.A., Psychology
Certifications & Licensure
NJ State Medical License 2006 - 2027
NY State Medical License 1987 - 2026
CA State Medical License Active through 2014
Awards, Honors, & Recognition
- Top Doctors: New York Area Castle Connolly, 1999-2004
- Business Excellence Award Novartis Oncology, 2008
- President’s Award Novartis Oncology, 2006, 2009
Publications & Presentations
PubMed
- 8 citationsJAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyAlessandro M. Vannucchi, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi
Journal of Clinical Medicine. 2021-08-23 - 11 citationsComparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk...Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey
Hematological Oncology. 2021-07-05 - 28 citationsAnalysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares
Leukemia & Lymphoma. 2021-03-21
Journal Articles
- The Palatability and Tolerability of Deferasirox Taken with Different Beverages or FoodsGoldberg SL, Giardina PJ, Chirnomas D. Esposito J, Paley C, Vichinsky E, Pediatric Blood Cancer, 9/1/2013
- Phase II Trial of Panobinostat, an Oral Pan-Deacetylase Inhibitor in Patients with Primary Myelofibrosis, Post-Essential Thrombocythaemia, and Post-Polycythaemia Vera ...Deangelo D, Mesa R, Fiskus W, Tefferi A. Paley C, Wadleigh M, Ritchie E, Snyder D, Degna K. Ganguly S, Ondovik M, Rine J, Bhalla K, Br J. Haematol, 5/23/2013
- Age-Related Treatment Patterns in Sickle Cell Disease Patients and the Associated Sickle Cell Complications and Healthcare CostsBlinder M, Vekeman F, Sasane M, Trahey A, Paley C, Duh M, Pediatric Blood Cancer, 5/1/2013
Books/Book Chapters
Abstracts/Posters
- PANORAMA 2: Panobinostat, Bortezomib, and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Myeloma - Poster PresentationRichardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gaspareto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley C, Lonial S, IMW, 1/1/2013
- Clinical Response by Baseline Characteristics in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma Treated with Panobinostat, Bortezomib, and Dexametha...Richardson P, Schlossman R, Alsina M, Coutre SE, Gasparetto C, Mukhopadhyay S. Ondovik M, Khan M, Paley C, Lonial S, ASCO, EHA, 1/1/2013
- Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease - Oral PresentationBlinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS, ASH, 1/1/2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









